Microtubule stabilising agents for cancer chemotherapy

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 5, 2009, Pages 607-622

  Zhao, Ying ^a,b   Fang, Wei Shuo ^a,b   Pors, Klaus ^c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Anticancer; Chemotherapy; Discodermolide; Epothilone; Microtubule stabilising agent; Taxane

Indexed keywords

21 AMINOEPOTHILONE B; 3' TERT BUTYL 3' N TERT BUTYLOXYCARBONYL 4 DEACETYL 3' N DEBENZOYL 3' DEPHENYL 4 O METHOXYCARBONYLPACLITAXEL; 9,10 DIDEHYDROEPOTHILONE D; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOSTREPTIN; DICTYOSTATIN; DISCODERMOLIDE; DJ 927; DOCETAXEL; ELEUTHEROBIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; FR 182877; IDN 5390; ISOLAULIMALIDE; IXABEPILONE; LAULIMALIDE; MAC 321; MST 997; ORTATAXEL; PACLITAXEL; PELORUSIDE A; SAGOPILONE; SARCODICTYIN A; SARCODICTYIN B; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BINDING SITE; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ISOLATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG TOXICITY; METASTASIS; MICROTUBULE; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PHARMACOPHORE; RECOMMENDED DRUG DOSE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MICROTUBULES; NEOPLASMS; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS;

EID: 67649344837     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902775713     Document Type: Review

References (132)

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265 •• A review on microtubule and microtubule targeted drugs. (Pubitemid 38525281)
2. Altmann K-H, Gertsch J. Anticancer drugs from nature - natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 2007;24:327-357 •• A recent and comprehensive review on natural products based MSAs and their derivatives. (Pubitemid 46504987)
3. Molodtsov MI, Ermakova EA, Shnol EE, et al. A molecular-mechanical model of the microtubule. Biophys J 2005;88:3167-3179 (Pubitemid 40586570)
4. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov Today 2001;6:1153-1164 (Pubitemid 32999054)
5. Altmann K-H. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr Opin Chem Biol 2001;5:424-431 (Pubitemid 32900515)
6. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone. Cancer Res 2003;63:6026-6031
7. Honore S, Kamath K, Braguer D, et al. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res 2004;64:4957-4964 (Pubitemid 38924543)
8. Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007;13:2849-2854 (Pubitemid 46849557)
9. Jordan MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-825 (Pubitemid 26055472)
10. Trielli MO, Andreassen PR, Lacroix FB, et al. Differential taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J Cell Biol 1996;135:689-700 (Pubitemid 26372925)
11. Chen J-GC, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002;14:1935-1938 (Pubitemid 34408432)
12. Chen J-GC, Yang C-PHY, Cammer M, Horwitz SB. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003;15:7891-7899 (Pubitemid 37466724)
13. Kim T-J, Lim Y, Kim D-W, et al. Epothilone D, a microtubule-stabilizing compound, inhibits neointimal hyperplasia after rat carotid artery injury by cell cycle arrest via regulation of G1-checkpoint proteins. Vasc Pharmcol 2007;47:229-237 (Pubitemid 47451829)
14. Rodi DJ, Janes RW, Sanganee HJ, et al. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol 1999;285:197-203 (Pubitemid 29034037)
15. Byrd CA, Bornmann W, Erdjument-Bromage H, et al. Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1999;96:5645-5650 (Pubitemid 29234672)
16. Bhat N, Perera PY, Carboni JM, et al. Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression. J Immunol 1999;162:7335-7342 (Pubitemid 29277709)
17. Boehmerle W, Splittgerber U, Lazarus MB, et al. Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc Natl Acad Sci USA 2006;103:18356-18361
18. Aoki S, Morohashi K, Sunoki T, et al. Screening of paclitaxel-binding molecules from a library of random Peptides displayed on T7 phage particles using paclitaxel-photoimmobilized resin. Bioconjug Chem 2007;18:1981-1986 (Pubitemid 350219999)
19. Zimmer SM, Liu J, Clayton JL, et al. Paclitaxel binding to human and murine MD-2. J Biol Chem 2008;283:27916-27926
20. André N, Braguer D, Brasseur G, et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 2000;60:5349-5353 (Pubitemid 30761239)
21. Khawaja NR, Carré M, Kovacic H, et al. Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. Mol Pharmacol 2008;74:1072-1083
22. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents VI. The isolation and structure of taxol a novel anti-leukemic and anti-tumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327
23. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-667 (Pubitemid 9114288)
24. Nogales E, Wolf SG, Khan IA, et al. Structure of tubulin at 6.5Å and location of the taxol-binding site. Nature 1995;375:424-427
25. Nogales E. Structural insights into microtubule function. Annu Rev Biochem 2000;69:277-302 (Pubitemid 30792211)
26. Safavy A. Taxane derivatives for targeted therapy of cancer. US6191290; 2001
27. Sohn Y-S, Ji D-E, Jun Y-J, Lee H-J. Water soluble micelle-forming and biodegradable cyclotriphosphazene-taxol conjugate anticancer agent and preparation method thereof. US20070292384; 2007
28. Polizzi D, Pratesi G, Monestiroli S, et al. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res 2000;6:2070-2074 (Pubitemid 30305107)
29. Sampath D, Discafani CM, Loganzo F, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2003;2:873-884
30. Beeram M, Takinoto CH, Gadgeel S, et al. Phase I and pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. J Clin Oncol 2004;22:2028
31. Broker LE, deVos FY, Gall H, et al. A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors. J Clin Oncol 2004;22:2029
32. Sampath D, Greenberger LM, Beyer C, et al. Preclinical pharmacologic evaluation of MST-997, and orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models. Clin Cancer Res 2006;12:3459-3469 (Pubitemid 43910892)
33. Ferlini C, Gallo D, Scambia G. New taxanes in development. Expert Opin Investig Drugs 2008;17:335-347 (Pubitemid 351578186)
34. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2007;2:920-942 • A recent review on SAR studies of taxanes to overcome multi-drug resistance.
35. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-7295 (Pubitemid 37487160)
36. Shirakawa K, Takara K, Tanigawara Y, et al. Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res 1999;90:1380-1386 (Pubitemid 30032078)
37. Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001;298:1236-1242 (Pubitemid 32761945)
38. Yang C-G, Barasoain I, Li X, et al. Overcoming tumor drug resistance with high-affinity taxanes: a SAR study of C2-modified 7-acyl-10-deacetyl cephalomannines. ChemMedChem 2007;2:691-701
39. Ferlini C, Raspaglio G, Cicchillitti L, et al. Looking at drug resistance mechanisms for microtubule interacting drugs: dose TUBB3 work? Curr Cancer Drug Targets 2007;7:704-712
40. Kavallaris M, Kuo DY-S, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-1293 (Pubitemid 27386315)
41. Mozzetti S, Ferlini C, Concolino P, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;298:298-305 (Pubitemid 40075808)
42. Dumontet C, Isaac S, Souquet P-J, et al. Expression of class III β-tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005;92:E25-30
43. Sève P, Mackey J, Isaac S, et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-2007 (Pubitemid 43056983)
44. Banerjee A. Increased levels of tyrosinated α-, βIII-, and βIV-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun 2002;293:598-601
45. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 2005;19:1299-1301 (Pubitemid 41113729)
46. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006;97:813-820 (Pubitemid 44151259)
47. Agoulnik S, Kuznetsov G, Littlefield BA. Tubulin isotype screening in cancer therapy using hemiasterlin analogs. US20060148014; 2006
48. Agoulnik S, Kuznetsov G, Littlefield BA. Tubulin isotype screening in cancer therapy using halichondrin B analogs. US20060154312; 2006
49. Ferlini C, Raspaglio G, Mozzetti S, et al. The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance. Cancer Res 2005;65:2397-405 • Describes a βIII-tubulin-targeting taxane. (Pubitemid 40490151)
50. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-2333
51. Verrills NM, Flemming CL, Liu M, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 2003;10:597-607 (Pubitemid 36940936)
52. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on α, β-tubulin by electron crystallography. Science 2004;305:866-869
53. Feyen F, Cachoux F, Gertsch J, et al. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc Chem Res 2008;41:21-31
54. Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007;18(Suppl 5):v9-v15 • A recent review on Phase I studies of epothilones.
55. Larkin JMG, Kaye SB. Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 2007;18(Suppl 5):v28-34 • A recent review on Phase II studies of epothilones.
56. Bristol-Myers Squibb Company. Methods of administering epothilone analogs for the treatment of cancer. EP1938821; 2008
57. Lee FYF, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201-212
58. Donovan D, Vahdat LT. Epothilones: clinical update and future directions. Oncology (Williston Park) 2008;22:408-416
59. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-3414 (Pubitemid 47310876)
60. Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 2008;13:214-221 (Pubitemid 351679896)
61. Higa GM, Abraham J. Ixabepilone: a new microtubule-targeting agent for breast cancer. Expert Rev Anticancer Ther 2008;8:671-681
62. O'Reilly T, Wartmann M, Brueggen J, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008;62:1045-1054
63. Hoffman J, Fichtmer I, Lemm M, et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 2009;11:158-166
64. Gunasekera SP, Gunasekera M, Longley RE, Schulte GK. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J Org Chem 1990;55:4912-4915 (Pubitemid 20269838)
65. Longley RE, Caddigan D, Harmody D, et al. Discodermolide-a new, marine-derived immunosuppressive compound. II. In vivo studies. Transplantation 1991;52:656-661
66. Gunasekera M, Gunasekera SP, Longley RE, Burres N. Discodermolide compounds, compositions containing same and methods of preparation and use. WO9101982; 1991
67. ter Haar E, Kowalski RJ, Hamel E, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996;35:243-250
68. Hung DT, Chen J, Schreiber SL. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem Biol 1996;3:287-293 (Pubitemid 126663327)
69. Kowalski RJ, Giannakakou P, Gunasekera SP, et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nudeation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997;52:613-622 (Pubitemid 27443983)
70. Kalesse M. The chemistry and biology of discodermolide. ChemBioChem 2000;1:171-175
71. Balachandran R, ter Haar E, Welsh MJ, et al. The potent microtubule-stabilizing agent (+)-discodermolide induces apoptosis in human breast carcinoma cells-preliminary comparisons to paclitaxel. Anticancer Drugs 1998;9:67-76
72. Longley RE, Gunasekera SP, Pomponi S. Discodermolide compounds and pharmaceutical compositions containing them for cancer therapy. WO9720835; 1997
73. Klein LE, Freeze BS, Smith III AB, Horwitz SB. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle 2005;4:501-507 (Pubitemid 41359741)
74. Martello LA, McDaid HM, Regl DL, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000;6:1978-1987 (Pubitemid 30305097)
75. Horwitz SB, McDaid HM, Martello LA. Method for treating neoplasia using combination chemotherapy. US20020065234; 2002
76. Honore S, Kamath K, Braguer D, et al. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res 2004;64:4957-4964 (Pubitemid 38924543)
77. Huang GS, Lopez-Barcons L, Freeze BS, et al. Potentiation of taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res 2006;12:298-304 (Pubitemid 43166207)
78. Paterson I, Florence GJ. The development of a practical total synthesis of discodermolide, a promising microtubule-stabilizing anticancer agent. Eur J Org Chem 2003;12:2193-2208 (Pubitemid 37140516)
79. Mickel SJ. Toward a commercial synthesis of (+)-discodermolide. Curr Opin Drug Discov Dev 2004;7:869-881 (Pubitemid 39643503)
80. Shaw SJ, Sundermann KF, Burlingame MA, et al. Toward understanding how the lactone moiety of discodermolide affects activity. J Am Chem Soc 2005;127:6532-6533 (Pubitemid 40664150)
81. Shaw SJ, Menzella HG, Myles DC, et al. Coumarin-derived discodermolide analogues possessing equivalent antiproliferative activity to the natural product - a further simplification of the lactone region. Org Biomol Chem 2007;5:2753-2755 (Pubitemid 47258231)
82. Smith III AB, Freeze BS, LaMarche MJ, et al. Design, synthesis, and evaluation of carbamate-substituted analogues of (+)-discodermolide. Org Lett 2005;7:311-314 (Pubitemid 40208696)
83. Isbrucker RA, Gunasekera SP, Longley RE. Structure-activity relationship studies of discodermolide and its semisynthetic acetylated analogs on microtubule function and cytotoxicity. Cancer Chemother Pharmacol 2001;48:29-36 (Pubitemid 32662433)
84. Gunasekera SP, Longley RE, Isbrucker RA. Acetylated analogues of the microtubule-stabilizing agent discodermolide: preparation and biological activity. J Nat Prod 2001;64:171-174 (Pubitemid 32198340)
85. Gunasekera SP, Paul GK, Longley RE, et al. Five new discodermolide analogues from the marine sponge Discodermia species. J Nat Prod 2002;65:1643-1648 (Pubitemid 35386795)
86. Jiang W, Kumar S, Robertson R, Wong S-M. Discodermolide compositions. US20070082945; 2007
87. Mita A, Lockhart AC, Chen T-L, et al. A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 weeks to adult patients with advanced solid malignancies. J Clin Oncol 2004;22:2025
88. Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006;54:72-84
89. Pettit GR, Cichacz ZA, Gao F, et al. Isolation and structure of the cancer cell growth inhibitor dicyostatin 1. J Chem Soc Chem Commun 1994;1994:1111-1112 (Pubitemid 24155638)
90. Pettit GR, Cichacz ZA. Isolation and structure of dictyostatin 1 and its use as anti-neoplastic agent. EP0680958; 1995
91. Isbrucker RA, Cummins J, Pomponi SA, et al. Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. Biochem Pharmacol 2003;66:75-82 (Pubitemid 36724901)
92. Madiraju C, Edler MC, Hamel E, et al. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. Biochemistry 2005;44:15053-15063 (Pubitemid 41612284)
93. Florence GJ, Gardner NM, Paterson I. Development of practical syntheses of the marine anticancer agents discodermolide and dictyostatin. Nat Prod Rep 2008;25:342-375
94. Lindel T, Jensen PR, Fenical W, et al. Eleutherobin, a new cytotoxin class that mimics paclitaxel (Taxol) by stabilizing microtubules. J Am Chem Soc 1997;119:8744-8745 (Pubitemid 27406321)
95. Long BH, Carboni JM, Wasserman AJ, et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol®). Cancer Res 1998;58:1111-1115 (Pubitemid 28183193)
96. Ciomei M, Albanese C, Pastori W, et al. Sarcodictyins: a new class of marine derivatives with mode of action similar to taxol [abstract 30]. Proc Am Assoc Cancer Res 1997;38:5
97. Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 1999;38:5490-5498 (Pubitemid 129514855)
98. Nicolaou KC, Vandelft F, Hosokawa S, et al. Sarcodictyin and eleutherobin useful for stabilizing microtubules. WO9921862; 1999
99. Andersen RJ, Roberge M, Britton RA, de Silva ED. Antimitotic eleuthesides. WO0300711; 2003
100. Battistini C, Ciomei M, Pietra F, et al. Terpenoidic derivatives useful as antitumor agents. US5869514; 1999
101. Mongelli N, Menichincheri M, Ciomei M, et al. Simplified sarcondictyin derivatives as anti-tumor agents. US20050038112; 2005
102. Mooberry SL, Tien G, Hernandez AH, et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stubilizing agents. Cancer Res 1999;59:653-660 (Pubitemid 29076064)
103. Corley DG, Herb R, Moore RE, et al. Laulimalide. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator. J Org Chem 1988;53:3644-3646 (Pubitemid 18182797)
104. Mooberry SL, Davidson BS. Laulimalide microtubule stabilizing agents. US20020198256; 2002
105. Pryor DE, O'Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002;41:9109-9115 (Pubitemid 34787268)
106. Pineda O, Farràs J, Maccari L, et al. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg Med Chem Lett 2004;14:4825-4829 (Pubitemid 39165575)
107. Gapud EJ, Bai R, Ghosh AK, Hamel E. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. Mol Pharmacol 2004;66:113-121 (Pubitemid 38822093)
108. Clark EA, Hills PM, Davidson BS, et al. Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Mol Pharm 2006;3:457-467 (Pubitemid 44351929)
109. Lu H, Murtagh J, Schwartz EL. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (Taxotere). Mol Pharmacol 2006;69:1207-1215
110. Mulzer J, Öhler E. Microtubule-stabilizing marine metabolite laulimalide and its derivatives: synthetic approaches and antitumor activity. Chem Rev 2003;103:3753-3786
111. Liu J, Towle MJ, Cheng H, et al. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 2007;27:1509-1518
112. West LM, Northcote PT, Battershill CN. Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 2000;65:445-449 (Pubitemid 30061125)
113. Hood KA, West LM, Rouwé B, et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res 2002;62:3356-3360 (Pubitemid 34651377)
114. Gaitanos TN, Buey RM, Díaz JF, et al. Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 2004;64:5063-5067 (Pubitemid 39006519)
115. Hamel E, Day BW, Miller JH, et al. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 2006;70:1555-1564 (Pubitemid 44776415)
116. Wilmes A, Bargh K, Kelly C, et al. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharm 2007;4:269-280 (Pubitemid 46640603)
117. Huzil JT, Chik JK, Slysz GW, et al. A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol 2008;378:1016-1030
118. Sato B, Muramatsu H, Miyauchi M, et al. A new antimitotic substance, FR182877: I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 2000;53:123-130
119. Sato B, Nakajima H, Hori Y, et al. A new antimitotic substance, FR182877: II. The mechanism of action. J Antibiot 2000;53:204-206 (Pubitemid 30135881)
120. Edler MC, Buey RM, Gussio R, et al. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site. Biochemistry 2005;44:11525-11528 (Pubitemid 41209088)
121. Buey RM, Calvo E, Barasoain I, et al. Cyclostreptin binds covalently to microtubule pores and luminal taxoid binding sites. Nat Chem Biol 2007;3:117-125 (Pubitemid 46134999)
122. Smith III AB, LaMarche MJ, Falcone-Hindley M. Solution structure of (+)-discodermolide. Org Lett 2001;3:695-698 (Pubitemid 33627013)
123. Sánchez-Pedregal VM, Kubicek K, Meiler J, et al. The tubulin-bound conformation of discodermolide derived by NMR studies in solution supports a common pharmacophore model for epothilone and discodermolide. Angew Chem Int Ed Engl 2006;45:7388-7394 (Pubitemid 44786965)
124. Ojima I, Chakravarty S, Inoue T, et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci USA 1999;96:4256-4261 • Describes the common pharmacophore of five MSAs. (Pubitemid 29190323)
125. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000;97:2904-2909 (Pubitemid 30159270)
126. Ganesh T, Guza RC, Bane S, et al. The bioactive taxol conformation on β-tubulin: Experimental evidence from highly active constrained analogs. Proc Natl Acad Sci USA 2004;101:10006-10011 (Pubitemid 38891186)
127. Geney R, Sun L, Pera P, et al. Use of the tubulin bound paclitaxel conformation for structure-based rational drug design. Chem Biol 2005;12:339-348 (Pubitemid 40406281)
128. Ghosh AK. Microtubule stabilizing compounds. US20030203929; 2003
129. Bergstralh DT, Ting JP-Y. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 2006;32:166-179
130. Kaye SB. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 1998;1:S15-9 (Pubitemid 28482336)
131. Persidis A. Cancer multidrug resistance. Nat Biotechnol 1999;17:94-95 (Pubitemid 29037219)
132. Sparreboom A, Nooter K. Dose P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist Updat 2000;3:357-363